Recalls & Warnings December 17, 2020 FTC Crackdown on Six Deceptive CBD Products On December 17, 2020, the FTC announced that it is taking action against six companies for selling CBD products with unsupported and deceptive health claims that they can treat a variety of conditions, including cancer, heart disease, hypertension, Alzheimer's disease, and others
[13] In GPX1 (-/-) mice, oxidant formation is increased, endothelial NO synthase is deregulated, and adhesion of leukocytes to cultured endothelial cells is increased
This event has passed
Typical requirements include: BMI 40 documented atherosclerotic cardiovascular disease use of a specific Wegovy prior authorization form Key Takeaways Determine whether the patient ever had diabetes Use the correct diagnosis code on the prior authorization Verify whether the insurance plan covers weight-management medications Document baseline weight when starting therapy Consider secondary indications for Medicare coverage Final Thoughts Prior authorizations for GLP-1 medications can be complex and time-consuming
Similarly, Ozempic is not specifically approved for weight loss
Arch Neurol 64:683688